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Cytomegalovirus (CMV), the beta-human herpesvirus type 5 (HHV-5), is a major cause of morbidity in immunocompromised hosts, 
especially recipients of allogeneic hematopoietic cell transplantation (HCT) or solid organ transplantation. The standard-of-care 
approach to CMV prevention based on CMV surveillance-guided preemptive therapy is being challenged by the recent approval of 
letermovir (LMV) for primary prophylaxis. Real-word clinical data show dramatic improvement in the reduction of risk of CMV infection 
and any CMV viremia in all studies performed so far. LMV is the drug that is breaking the paradigm of preemptive therapy with shift 
to prophylaxis. A summary of reported data presented in 2019 annual meetings of American Society of Transplantation and Cellular 
Therapy (ASTCT), European Society for Blood and Marrow Transplantation (EBMT) and American Society of Hematology (ASH), as well 
as already published results, is presented in this review. A total number of 401 adult high-risk patients on primary prophylaxis after HCT 
were reported in 11 studies up to January 1, 2020. It was shown that fewer patients in the LMV arms had any CMV reactivation or need for 
CMV treatment compared with the any other prophylactic or preemptive approaches. In conclusion, LMV is much highly effective than 
CMV-guided preemptive therapy in preventing CMV infection and CMV disease. The use of LMV in prophylaxis results in an improvement 
in overall survival during the first 24 and 48 weeks. LMV has a favorable safety profile, as it does not cause myelotoxicity. Current 
guidelines of European Conference on Infections in Leukemia (ECIL7) recommend LMV for the use in prophylaxis of CMV infection in 
patients after allogeneic hematopoietic cell transplant.
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Introduction
Cytomegalovirus (CMV), the beta-human herpesvirus type 5 (HHV-5), 
is a major cause of morbidity in immunocompromised hosts, especially 
recipients of allogeneic hematopoietic cell transplantation (HCT) 
or solid organ transplantation (SOT). On the other hand, primary 
infection with CMV in healthy individuals is usually asymptomatic, or 
it manifests as a self-limited febrile illness, such as mononucleosis-
like syndrome.
Primary CMV infection or reactivation during immune suppression is 
associated with increased morbidity and mortality. CMV infection is a 
serious condition for immune system. It can adversely affect transplant 
outcomes directly or indirectly. Direct increased organ toxicity is the 
effect of the infection itself, while indirect toxicity is caused by associated 
side effects of antiviral therapy. This leads to a higher risk of bacterial 
and fungal infections. The most frequent clinical manifestations of CMV 
infection and disease in immunosuppressed patients are pneumonia, 
enteritis, bone marrow suppression, hepatitis, and retinitis [1]. It has 
been proven that CMV seropositive status, CMV infection, and CMV 
disease decrease survival after HCT [2, 3, 4].
As it is of utmost importance to prevent CMV infection and CMV 
disease, this paper was aimed to present and compare the strategies 
of prophylaxis and preemptive treatment against CMV after allo-HCT, 
with focus on (analysis of) current evidence-based possibilities of 
prevention of CMV infection reported in 2019. This article is based on 
previously conducted studies and does not involve any new studies of 
human or animal subjects performed by the author.
Definitions
Recently, updated definitions on CMV infection, CMV resistant 
infection, CMV disease, and CMV-resistant disease were published 
[1, 5, 6, 7]. Briefly:
•  CMV infection is defined as virus isolation or detection of viral 
proteins (antigens) or nucleic acid in any body fluid or tissue 
specimen.
•  CMV replication indicates evidence of viral multiplication and is 
sometimes used instead of CMV infection.
•  Primary CMV infection is defined as the first detection of CMV 
infection in an individual who has no evidence of CMV exposure.
•  Recurrent CMV infection is defined as new CMV infection in a 
patient with previous evidence of CMV infection who has not had 
virus detected for an interval of at least 4 weeks during active 
surveillance. Recurrent infection may result from reactivation of 
latent virus (endogenous) or reinfection (exogenous).
•  CMV reinfection is defined as detection of a CMV strain that is 
distinct from the strain that caused the initial infection.
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•  CMV reactivation is likely if the two viral strains (prior and current 
strain) are found to be indistinguishable either by sequencing 
specific regions of the viral genome or by using various molecular 
techniques that examine genes known to be polymorphic.
•  Symptomatic CMV infection is diagnosed in patients developing 
symptoms (fever with or without bone marrow suppression) and 
who have CMV virions, antigens, or nucleic acid detectable but 
with no sign of CMV end-organ disease.
•  CMV disease is diagnosed in patients with symptoms and/
or signs from the affected organ together with the detection of 
CMV by a test with appropriate sensitivity and specificity from 
an organ in a biopsy or samples from other invasive procedures, 
with exception for CMV retinitis, for which typical findings by 
ophthalmologic examination are sufficient.
•  Refractory CMV infection means CMV viremia that increases 
(>1 log10 increase in CMV DNA levels) after at least 2 weeks of 
appropriately dosed antiviral therapy.
•  Probable refractory CMV infection means persistent viral load 
(CMV viral load at the same level or higher but <1 log10 increase 
in CMV DNA levels) after at least 2 weeks of appropriately dosed 
antiviral therapy.
•  Refractory CMV end-organ disease involves worsening in signs 
and symptoms or progression into end-organ disease after at 
least 2 weeks of appropriately dosed antiviral therapy.
•  Probable refractory CMV end-organ disease involves lack of 
improvement in signs and symptoms after at least 2 weeks of 
appropriately dosed antiviral drugs.
•  Antiviral drug resistance involves viral genetic alteration that 
decreases susceptibility to one or more antiviral drugs.
Epidemiology of CMV infection and CMV 
disease after HCT
Detailed analysis of incidence of CMV recurrence in groups of 
immunocompromised patients showed that median rate of CMV 
infection (recurrence) was estimated to be 37% after allo-HCT 
and 12% after auto-HCT, 5% in non-transplant hematological 
malignancies, 14% in recipients of anti-CD52 therapy, 30% in SOT 
recipients, and 21% in primary immunodeficiencies. The highest risk 
of CMV infection and CMV disease after HCT was reported for CMV-
seropositive recipients (R), regardless on donor (D) serostatus. The 
odds ratio for CMV infection was higher for CMV-serostatus R+ vs 
R- transplants (odds ratio [OR] = 8.0), CMV-serostatus D-/R+ vs D+/
R+ transplants (OR = 1.2), unrelated/mismatched vs matched sibling 
donor transplants (OR = 1.6), and acute graft versus host disease 
(GVHD) vs others (OR = 3.2) [8]. Recent nationwide analysis in 
Poland showed the incidence of CMV infection of 28.9% in pediatric 
and 24.7% in adult allo-HCT recipients [9, 10, 11].
Strategies for managing CMV infection 
following HCT
Current universal (nonpharmacological) management strategies 
to prevent primary CMV infection in CMV-seronegative recipients 
of allo-HCT include donor selection, transfusion policy (i.e., tested 
safe blood products, including leukodepleted and filtered red cell 
and platelet concentrates), and non-specific hygiene preventive 
measures in hospital environment, including training for patients 
(e.g., to perform regular handwashing and to avoid sharing cups, 
glasses, and eating tools) (Tab. I).
Recommendations for pre-transplant setting are based on testing 
of all patients and donors for CMV IgG antibodies. The choice of 
a donor includes CMV-seronegative donor for a CMV-seronegative 
recipient and CMV-seropositive donor for a CMV-seropositive 
recipient (if possible) in the setting of myeloablative unrelated allo-
HCT; however, there is no priority in the donor CMV serostatus for a 
CMV-seropositive recipient designed for non-T-cell-depleted haplo-
HCT with post-transplant cyclophosphamide (PTCy) [6].
Current pharmacological management strategies to prevent CMV 
infection (primary or reactivation) or CMV disease in the recipient of 
allo-HCT include prophylaxis or preemptive therapy:
•  Prophylaxis – it is a strategy where antiviral agents are given 
to a patient to prevent a primary, reactivated, or recurrent CMV 
infection.
•  Preemptive therapy – it is a strategy where antiviral agents are 
given for an asymptomatic CMV infection detected by a specific 
screening assay [5, 6].
Antiviral anti-CMV prophylaxis
In order to prevent CMV disease, early CMV replication should be 
prevented. Retrospective analysis of seropositive patients monitored 
by qPCR has shown in multivariate analysis a significant effect of 
presence of any level of CMV viremia on all-cause mortality and non-
relapse mortality both during early and late post-transplant period up 
to day +365, even despite the use of preemptive therapy [4]. The 
fact that CMV replication is associated with mortality is the principal 
reason to use prophylaxis against CMV infection after allo-HCT. Apart 
from adverse effects of CMV replication, another reason is that CMV 
seropositivity in the patient decreases survival [2, 3].
Prophylaxis of CMV infection was usually not being used so far in 
allo-HCT, because data from previous studies and strategy from 
many years have shown that:
• Aciclovir/valaciclovir are not effective enough.
• Ganciclovir and foscarnet are effective but toxic in HCT recipients.
•  Valganciclovir is effective in SOT (but causes myelosuppression, 
thus is used significantly limited in HCT recipients).
Table I. Strategies for managing CMV infection following hematopoietic cell transplantation
Strategy Management
Universal prophylaxis To prevent CMV infection/reactivation
Risk-adapted prophylaxis To prevent CMV infection/reactivation in high-risk subgroups
Preemptive therapy Treatment of (a)symptomatic CMV infection detected by a screening assay to prevent CMV disease
Therapy Treatment of end-organ CMV disease
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• Drug resistance and intolerance remain as problems.
•  Failure of Phase III studies for prophylaxis with maribavir (MBV) 
and brincidofovir (BCV).
Current European Conference on Infections in Leukemia (ECIL7) 
recommendations on CMV prophylaxis in allo-HCT are presented 
in table II. The main pitfall of prophylaxis strategy is unnecessary 
treatment of patients who will not develop CMV infection or disease 
(Tab. III). Because of toxicity and limited efficacy, there is no 
ideal agent available due to: myelosuppression (ganciclovir) and 
renal toxicity (foscarnet); more bacterial and fungal infection, and 
breakthrough infection. Additionally, no improvement for overall 
survival (OS) was shown so far, while delayed immune reconstitution, 
late CMV disease, and potential for development of resistance were 
observed with the use of available anti-CMV antivirals.
Preemptive therapy against CMV disease
Preemptive therapy is regarded as the standard strategy for CMV 
prevention after allo-HCT, and current guidelines recommend this 
approach [5, 6, 12, 13]. Using this strategy, patients are monitored 
weekly for CMV reactivation using CMV nucleic acid test (NAT) by 
PCR. Detection of asymptomatic CMV reactivation above a “viral 
load threshold” prompts the initiation of preemptive treatment to 
prevent progression to clinical disease.
Rationale for monitoring preemptive treatment is based on (A) 
availability of sensitive diagnostic test, recently WHO standardized 
[14]; (B) predictivity of a positive result for development of CMV 
disease, except for gastrointestinal infection and retinitis; (C) 
knowledge that early intervention can prevent disease [15]; and (D) 
availability of an effective (and relatively safe) antiviral drug.
Current ECIL7 first-line preemptive therapy recommendations for 
allo-HCT recipients include [6]:
•  Either IV ganciclovir or foscarnet can be used for first-line 
preemptive therapy.
•  Valganciclovir can be used in place of IV ganciclovir or foscarnet 
(except in patients with severe gastrointestinal GVHD).
• The combination of foscarnet+ganciclovir is not recommended. 
•  The choice of drug depends on time after HCT, risk of toxicity, 
and previous antiviral drug exposure.
The pitfall of preemptive therapy is that the strategy of viremia-
guided preemptive therapy still allows for CMV reactivation. Although 
preemptive treatment of asymptomatic CMV reactivation is efficacious 
in reducing tissue-invasive CMV disease, emerging data suggest a 
negative long-term effect of CMV replication [4].
Anti-CMV antivirals
Currently available anti-CMV drugs include (val)ganciclovir, foscarnet, 
cidofovir, and acyclovir (plus valacyclovir and famciclovir). Three new 
antiviral agents have emerged in recent times, including letermovir 
(LMV), MBV, and BCV, enhancing ability to prevent and treat CMV. All 
these drugs were efficacious in prophylaxis in Phase II studies [17, 
18, 19]; however, BCV [20] and MBV [21] failed in Phase II studies. 
While LMV is already licensed in the USA and Europe, the role of 
MBV and BCV is still investigational, although MBV was shown to be 
effective in preemptive treatment [22] and for refractory and resistant 
CMV infection [23].
LMV belongs to a new class of compounds. Chemically, it is 
3,4-dihydro-quinazoline-4-yl-acetic acid derivative compound. It 
inhibits CMV through a novel mechanism involving the viral terminase 
Table II. Current ECIL7 recommendations on CMV prophylaxis in allogeneic HCT
Drug Grading References Comment
Letermovir AI Marty et al., N Engl J Med 2017 
Valaciclovir BI Ljungman et al., Blood 2002
Winston et al., Clin Infect Dis 2003
Association with preemptive strategy; causes severe myelo-
suppression
Ganciclovir CI Winston et al., Ann Intern Med 1993
Goodrich et al., Ann Intern Med 1993
Causes myelosuppression
Aciclovir CI Prentice et al., Lancet 1994 Less efficient than valaciclovir
Foscarnet DII Ordemann et al., Ann Hematol 2000
Bregante et al., Bone Marrow Transplant 2000
Grading: A – strongly recommended; B – generally recommended; C – optionally (weakly) recommended; D – not recommended; I – based on randomized trial; 
II - based on nonrandomized clinical studies.
Table III. CMV management strategies: advantages and disadvantages of prophylaxis and preemptive therapy
Advantages Disadvantages
Antiviral prophylaxis Efficacious for CMV disease prevention
Reduce early CMV reactivation
Can prevent direct and indirect effects
Viral load monitoring not required
CMV disease may occur without detectable CMV DNAemia
High rate of myelo- and nephrotoxicity
Risk of overtreatment
Risk of delayed-onset “post-prophylaxis” CMV infection and 
disease
Drug cost
May delay CMV-specific immune reconstitution
Preemptive therapy Efficacious for CMV disease prevention
Reduce overall drug cost
Reduce risk of drug toxicity (e.g., neutropenia)
Targets patients at the highest risk
May improve CMV-specific immune reconstitution
Does not prevent early CMV reactivation
Logistical nature of CMV surveillance and clinical follow-up
Potential to miss cases of CMV disease not preceded by DNAemia 
or antigenemia
Relies on availability of CMV testing
Concern for drug resistance
Modified from Razonable, COID 2018 [16].
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complex and shows potent anti-CMV activity in vitro and in vivo, but 
not against other viruses. No cross-resistance with drugs currently 
used in the treatment of CMV was observed [24].
When administered orally, its bioavailability is 94% in healthy 
individuals. In allo-HCT recipients, it is only 35%; however it is 
increased to 85% in the presence of cyclosporine. It is excreted 93% 
as feces and 70% as unchanged drug. Owing to only a minimal renal 
excretion, there is no need for renal dose adjustments.
After successful Phase III study [25], its clinical use is licensed by 
US Food and Drug Administration (FDA) (11 August 2017) followed 
by European Medicines Agency (EMA) (10 November 2017) for 
clinical use for antiviral prophylaxis to prevent CMV in at-risk CMV-
seropositive allo-HCT recipients. Prior to starting prophylaxis, a 
negative viral load should be documented. During LMV prophylaxis, 
CMV PCR surveillance is necessary to monitor breakthrough CMV 
infection. The recommended dose of LMV is 480 mg once daily or 
240 mg once daily in the presence of cyclosporine for prophylaxis. 
This is because cyclosporine increases LMV levels. Another potential 
important interaction is reduction of voriconazole levels by LMV.
Current considerations for use include necessity to document a 
negative viral load prior to starting prophylaxis. CMV PCR surveillance 
should be performed to monitor breakthrough CMV infection during 
LMV prophylaxis. Additionally, potential interactions (cyclosporine 
increases LMV levels, LMV reduces voriconazole levels, and others) 
should be checked.
LMV is approved by FDA and EMA as antiviral prophylaxis for the 
prevention of CMV in allogeneic HCT recipients, while it is not 
approved for preemptive treatment of asymptomatic CMV infection 
and treatment of CMV disease, including those due to GCV-resistant 
virus, and secondary CMV prophylaxis, and in children.
Real-world experience with LMV in primary 
prophylaxis of CMV after HCT in adult patients
In order to analyze real-world evidence of LMV use for CMV 
prophylaxis in clinical practice, review of data reported in studies 
on primary prophylaxis with LMV in adults, presented on major 
hematology/HCT (American Society of Transplantation and Cellular 
Therapy (ASTCT/TCT); European Society of Blood and Marrow 
Transplantation (EBMT); and American Society of Hematology 
(ASH)) annual meetings in 2019, supplemented with two papers 
published in 2019, was performed [26, 27]. No other congress reports 
on the use of LMV in primary prophylaxis in high-risk allo-HCT adult 
patients were found.
Data from 11 studies on primary anti-CMV prophylaxis with LMV 
were presented or published in 2019. A total number of 401 patients 
were reported to be administered LMV (Tab. IV).
LTV use in a real-world setting was associated with substantial 
reduction in CMVi and cs-CMVi without any discernible 
myelosuppression in all studies in comparison to the cohort group in 
all studies with the control (usually historical) group. LMV prophylaxis 
was highly effective at mitigating CMV disease, CMV-related mortality, 
and the need for toxic CMV therapies. No significant adverse effects 
with LMV were observed in any study. Discontinuation of LMV was 
reported in few cases only.
LTV reduced the incidence of cs-CMVi including a trend towards 
decreased mortality. Patients on LTV prophylaxis had less CMV 
infections (21% vs 52%, p=0.01), less CMV disease (6% vs 10%, ns), 
less hospitalization for CMV infection treatment (7% vs 12%, ns), and 
lower all-cause mortality at day 100 (4% vs 14%, p=0.1) (abstract 
TCT #396). In multivariate analysis, two factors had an impact on 
Table IV.  Summary of reported data in abstracts on major hematology/HCT meetings or published in 2019
Study reference Number of patients High-risk patients Beginning of LMV CMVi rate vs control
Lau et al. (TCT, #127) 10 CMV R+ (CBT) +7 0% vs 82%
Foolad et al. (TCT, #396) 53 CMV R+ 21% vs 52%
Merchant et al. (TCT, #406) 30 CMV R+ +14 20% vs 63%
Dadwal et al. (TCT, #546) 59 Haplo, CBT, ATG +13 22% vs 41%
Lin et al. (TCT #128; EBMT #405; [27]) 53 CMV R+ (TCD, haplo) +7 5% (no control)
Robin et al. (EBMT, #406) 22 CMV R+ 0% (no control)
Derigs et al. (EBMT, #407) 35 CMV R+ 14% vs 58%
Kodiyanplakkal et al. (EBMT, #427) 31 CMV R+, ATG, anti-CD52 3% (no control)
Satake et al. (EBMT, #473) 13 Haplo, MUD, MMUD 0 0% (no control)
Karam et al. (ASH, #3269) 63 Haplo, MUD, CBT, ATG 27.6% vs 71%
Sharma et al. [26] 32 CBT (double/haplo), CMV R+ 0 0% vs 15%
TCT – Transplantation and Cellular Therapy Meeting; EBMT – European Society for Blood and Transplantation Meeting; ASH – American Society of Hematolo-
gy Meeting; CMVi – significant cytomegalovirus infection; HCT – hematopoietic cell transplantation; CBT – cord blood transplantation; MUD – matched unrela-
ted donor; MMUD – mismatched unrelated donor; haplo – haploidentical HCT; R+ – seropositive recipient; ATG – anti-thymocyte globulin; ND – no data
Source data: 
Abstracts from the 2019 TCT Meetings of ASBMT and CIBMTR, February 20-24, 2019 Houston, Texas. Biology of Blood and Marrow Transplantation  2019; 
25(3):A4-S442 (Supplement).
The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians. Poster Session. Bone Marrow Transplantation (2019) 
54:144–619. https://doi.org/10.1038/s41409-019-0559-4.
61 Annual Meeting of American Society of Hematology. Orlando (December 7-10, 2019). Blood 2019;134 (Supplement 1; November 13 2019):abstract 3269.
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occurrence of cs-CMVi at day +100: LMV use decreases the risk, 
while treatment of GVHD increased it. Notably, the positive impact 
of LMV was much stronger than the adverse effect of GVHD. The 
use of LMV was the only factor influencing the risk of occurrence of 
any detectable CMV viremia. Type of transplantation and donor CMV 
serostatus had no significant impact on CMV viremia or cs-CMVi 
infection (abstract TCT #396).
The LTV group had a significant reduction in CMV infection rate: 
22.4% vs 41.1% (p=0.008). The high-risk HCT patients had a higher 
benefit (22.2% vs 62.8%, p=0.004) than the low-risk group (22.8% 
vs 35.6%, ns) with LTV prophylaxis (abstract TCT#546). The low 
level CMVi, if any, resolved spontaneously in majority of patients 
with continued LTV prophylaxis and preemptive treatment was not 
necessary (abstract TCT#546).
The presented data suggest that CMV infection is considerably inhibited 
by administration of LMV early after HCT (abstract EBMT #473). LMV 
prophylaxis resulted in a low rate of CMV infection in high-risk, in-vivo 
TCD allo-HCT population (abstract EBMT #427). The safety and efficacy 
of LMV for the prophylaxis of CMV reactivation in seropositive patients 
after allo-HCT was confirmed (abstract EBMT #407).
Primary LTV prophylaxis significantly reduced CMV reactivation, and 
high-risk patients may benefit from extended prophylaxis. LTV was 
well tolerated. Additional studies are needed to determine optimal 
prophylaxis duration in high-risk allo-HCT (abstract TCT #128).
The benefit of LTV prophylaxis is reducing the risk of clinically 
significant CMV infection in unselected high-risk CMV-seropositive 
HCT patients, including a substantial number of high-risk transplant 
recipients. In contrast to the pivotal Phase III study, only a few 
CMV infections occurred past day 100 after discontinuation of LTV 
prophylaxis. No significant differences were observed in any other 
outcome variables including OS, non-relapse mortality, relapse, 
acute GVHD, or time to neutrophil or platelet recovery (abstract ASH 
#3269).
LMV is safe and effective compared with alternative prophylaxis 
approaches following CBT through day 100. No patients in the LMV 
group received additional CMV-directed treatment while on LMV [26]. 
LMV was well tolerated in CBT recipients. Data are very promising, 
and the extent of the benefit suggests that LMV could be a cost-
effective new standard of care in adult CBT (abstract TCT #127). 
Notably, because CMV is known to reactivate early after CBT [28], it 
is suggested to initiate LMV therapy on transplant day 0. No delays in 
engraftment or graft failure issues were observed with this approach 
[26].
A significant potential concern with LMV prophylaxis, particularly 
following CBT, is the possibility for delayed reactivation and CMV 
disease following discontinuation of the drug [26]. Until more robust 
data on this question are available, it was postulated that in patients 
at high risk for CMV reactivation, the prophylaxis with LMV should be 
continued. Serial CMV monitoring at least monthly through 6 months 
post CBT is recommended [26].
As delayed post-prophylaxis CMV reactivation remains a potential 
concern, the monitoring after day 100 should be mandatory. 
The duration of needed prophylaxis beyond day +100 requires 
investigation in CBT recipients (abstract TCT #127) and possibly 
in patients on immunosuppressive therapy for GVHD. Given its 
demonstrated benefits, LTV should be considered in all CMV-
seropositive allo-HCT recipients (abstract TCT #396).
Practical considerations
What is the current rationale for CMV prophylaxis?
The rationale for prophylaxis is clear. It has been proven that being 
seropositive is associated with increased mortality. In addition, any 
CMV replication in the patient, including replication in different organs 
and in different tissues, has negative impact on OS after HCT. The 
mortality data (in Phase III study and post hoc analysis) showed 
that both in 24 and 48 weeks after HCT, previous prophylaxis with 
LMV has decreases in all-cause mortality. This is additional rationale 
for prophylaxis. This rationale is stronger in the high-risk patients 
compared to low-risk patients, but in the post hoc analysis, after 
correction for risk status, it remains significant in both groups.
Will CMV prophylaxis change the clinical practice?
Prevention is a better way of managing the disease than treatment 
itself. This is of particular major value in case of high efficacy and 
safety. On the basis of existing data on LMV, both from the Phase 
III study and on the real-world data, both these conditions are being 
met. Therefore, prophylaxis is recommended, thus significantly 
changing current clinical practice.
How should patient be monitored during CMV 
prophylaxis?
Monitoring should be done, just as in the case of preemptive strategy. 
Breakthrough infection is still possible, although minimized. Another 
issue is the compliance of the patient, who is responsible for taking 
oral drug. Break in prophylaxis might lead to CMV reactivation and 
development of resistance.
Can LMV be considered for CMV treatment?
At the moment data are limited, and only a few cases are available. 
There are only uncertainties, such as dose. There are other antiviral 
drugs, such as acyclovir, where the dose for prophylaxis and dose 
for therapy are significantly different. Another important issue is that 
with different doses, the safety profile does not have to be the same. 
Lastly, the data on possible development of resistance to LMV in 
case of rapidly replicating CMV are also limited. From the practical 
point of view, it might be similar to fungal infections: a different drug 
is used for prophylaxis, and another one should be used to treat the 
breakthrough infection. On the other hand, it might be the approach 
for other indications in the future.
What should be done in case of low CMV viremia?
Existing data show that patients with a low level of viremia during 
LMV prophylaxis cleared the viremia while administration of LMV was 
not changed.
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When prophylaxis should be started and how long it 
should be used?
In the Phase III study, the rule was that that the drug should be started 
before day 28. Since both oral and intravenous formulae are available, 
the early start is always possible, regardless of patient tolerability of 
oral drug. It is important to start early, as CMV reactivation can occur 
even within first day after transplantation. As LMV is nontoxic, it could 
be started before the day of the transplant, what was done in several 
post-Phase-III studies. However, there are no interaction studies with 
chemotherapeutic agents used in conditioning; thus, it cannot be 
used before day 0.
So far, the only datum on the length of time is to use until week 
14. It was postulated in several studies that the prophylaxis should 
be prolonged. To answer this question, there is an ongoing study 
comparing the rationale of prophylaxis until 6 months. Both safety 
and efficacy are important issues.
For whom prophylaxis is recommended and for whom 
preemptive treatment?
For patients at a high-risk of CMV viremia, prophylaxis is 
recommended. There is no doubt about it, because the gain of LMV 
use is potentially much higher in high-risk patients, and preventing 
CMV viremia is beneficial for OS. On the other hand, prophylaxis 
was also effective and safe in low-risk patients. However, one should 
remember that only CMV-seropositive patients were included in these 
studies. Thus, with the current data, patients’ CMV seropositivity 
has already a strong indication for prophylaxis. All other allogeneic 
transplant recipients should be monitored for CMV viremia and 
preemptively treated in case of its positivity.
Should LMV prophylaxis be prolonged beyond day +100?
So far only data for up to week 14 are available. There is ongoing 
study comparing shorter versus longer prophylaxis with LMV. This 
study will answer the question about safety, efficacy, and rationale 
for prolonged prophylaxis. It is not obvious, as there are different 
scenarios with different antivirals.
Acyclovir can be taken safely for a year or so. On the other hand, in 
case of ganciclovir, the longer the use, the higher the risk of toxicity.
Conclusions
The presented real-world evidence confirms Phase III results of LMV 
in primary prophylaxis in adult CMV-seropositive recipients of allo-
HCT. Observational and retrospective studies showed safety and 
efficacy of LMV for the prophylaxis of CMV reactivation in seropositive 
patients after allo-HCT. LMV did not delay time to neutrophil and 
platelet engraftment in any of the studies. HCT patients with a high-
risk of CMV reactivation had most benefit with LTV prophylaxis.
LMV was much highly effective than CMV-guided preemptive therapy 
in preventing CMV infection and CMV disease [25]. The use of LMV 
in prophylaxis resulted in an improvement in OS during the first 24 
and 48 weeks [25, 29, 30]. LMV had a favorable safety profile, as it 
does not cause myelotoxicity.
LMV is an important addition to the current strategies for CMV 
prevention after allo-HCT. Its favorable efficacy and safety profile 
reopen door for another first-line option for antiviral prophylaxis, 
similar to CMV surveillance and preemptive therapy, for preventing 
CMV in allogeneic HCT recipients.
This new prophylaxis strategy in CMV+ patients after HCT results 
in reduced clinically significant CMV infections, less preemptive 
treatment and hospitalizations, and impact for lower all-cause 
mortality. First analyses and opinions suggest a significant cost-
effective benefit, particularly in the context of reduced adverse 
effects, such as GVHD and fungal and bacterial infections. Still, more 
real-life data are needed to confirm this approach.
The standard of care approach to CMV prevention based on CMV 
surveillance-guided preemptive therapy is being challenged by the 
recent approval of LMV for primary prophylaxis. Real-word clinical 
data show dramatic improvement in the reduction of risk of CMV 
infection and any CMV viremia in all studies performed so far. LMV 
is the drug that is breaking the paradigm of preemptive therapy with 
shift to prophylaxis.
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